Ankyra Therapeutics, Inc. — Form D
Ankyra Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2021-09-09. The offering totals $45.0M, of which $45.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-09-09
- Form: D
- Accession: 0001811511-21-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $45.0M
- Amount sold: $45.0M
- Investors: 14
- Date of first sale: 2021-08-26
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-412827
Issuer
- Name: Ankyra Therapeutics, Inc.
- CIK: 0001811511
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 83 NEWBURY STREET, BOSTON, MA, 02116
- Phone: 617-823-2399
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Philip Ferneau | Director | Hanover, NH |
| Tillman Gerngross | Director | Waltham, MA |
| Terrance McGuire | Director | Cambridge, MA |
| Ajay Royan | Director | Leawood, KS |
| Tillman Gerngross | Executive Officer | Waltham, MA |
Other filings by this issuer (1)
More